PDCD1 and cancer: The results of our cross-sectional study, aimed at assessing the prevalence of APA and, for the first time, AHA in cancer patients treated with anti-PD-1 and anti-PD-L1 antibodies, showed a statistically significant increase in the prevalence of AHA and APA in these patients compared with the control group.